Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.
- Sponsor
- Kantonsspital Aarau
- Study ID
- NCT02072057
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Cancer Cachexia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib — DRUG
Study Details
The aim of this study is to investigate the effects and safety of Ruxolitinib, a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) inhibitor for the treatment of tumor-associated cachexia in chronic wasting diseases.
Key Dates
- Start date
- Apr 20, 2014
- Status verified
- Feb 2019
- Primary completion
- Nov 30, 2018
- Completion
- Nov 30, 2018
Study Design
- Enrollment
- 8 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: RuxolitinibInterventional arm
Primary Outcome Measure
Body weight [ Time Frame: 3 months ]
Related Studies
- An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.PHASE2 · Recruiting · NGM Biopharmaceuticals, Inc · Los Angeles, California
- A First-in-Human Study of FID-022 in Solid Tumor PatientsRecruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida